Study evaluating in utero treatment for hypohidrotic ectodermal dysplasia seeks enrollees.

The article focuses on the EDELIFE trial, a multinational phase 2 study called EDELIFE that aims to evaluate the safety and effectiveness of in utero treatment for X-linked hypohidrotic ectodermal dysplasia (XLHED). It mentions the condition results from mutations in the EDA gene, leading to the absence of essential structures like teeth, hair, nails, and sweat glands, and the trial is investigating the use of ER004, a replacement protein, administered to affected fetuses in utero.